QR code

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

IntroductionRadium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study,...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Urbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, Sara Martinez-Breijo, Natalia Fernandez-Nuñez, Zulema Nogareda-Seoane, Miguel Garrido-Pumar, Javier Casas-Nebra, Gloria Muñiz-Garcia, Paula Portela-Pereira, Antonio Gomez-Caamaño, Daniel Adolfo Perez-Fentes, Lucia Santome-Couto, Martín Lázaro, Aurea Molina-Diaz, Ana Medina-Colmenero, Sergio Vazquez-Estevez
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2024-05-01
Reeks:Frontiers in Oncology
Onderwerpen:
metastatic castration-resistant prostate cancer
Radium-223
alkaline phosphatase
bone health agents
real-world data
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2024.1385466/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items